Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Altman

Dermatology Williamsville, NY Medical Doctor

NPI 1598764433 CMS profile 254125

8421 Sheridan Dr, Williamsville, NY 14221

Open in the dashboard

General payments

$22,999

1,165 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Altman of Williamsville, NY is reported in the CMS Open Payments database as having received $22,999 across 1,165 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,650 233
2024 General $3,621 222
2023 General $3,372 194
2022 General $3,238 196
2021 General $2,357 131
2020 General $1,269 75
2019 General $5,491 114

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Altman
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to David Altman were reported at $3,650. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year David Altman Dermatology median Middle half National median
2019 $5,491 $454 $129–$1,240 $163
2020 $1,269 $235 $81–$756 $114
2021 $2,357 $377 $108–$1,108 $132
2022 $3,238 $514 $143–$1,391 $149
2023 $3,372 $607 $159–$1,674 $160
2024 $3,621 $751 $204–$1,903 $164
2025 $3,650 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Ortho Dermatologics, a division of Bausch Health US, LLC $3,929 16 payments
  2. Janssen Biotech, Inc. $3,919 248 payments
  3. AbbVie, Inc. $3,062 190 payments
  4. UCB, Inc. $1,697 101 payments
  5. Novartis Pharmaceuticals Corporation $1,424 150 payments
  6. Regeneron Healthcare Solutions, Inc. $1,042 54 payments
  7. Lilly USA, LLC $1,040 44 payments
  8. Genzyme Corporation $865 43 payments
  9. Sun Pharmaceutical Industries Inc. $790 31 payments
  10. E.R. Squibb & Sons, L.L.C. $761 49 payments
  11. Other $4,470 239 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $18,413 1,153 payments
  2. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,680 1 payment
  3. Education $906 11 payments
Products named General payments · program years 2019–2025
  1. SILIQ $3,833 9 payments
  2. TREMFYA $3,051 160 payments
  3. SKYRIZI $1,628 96 payments
  4. DUPIXENT $1,084 49 payments
  5. TALTZ $985 42 payments
  6. Bimzelx $881 50 payments
  7. STELARA $874 89 payments
  8. SIMPONI ARIA $834 87 payments
  9. REMICADE $834 87 payments
  10. SIMPONI $834 87 payments
  11. Other $12,364 761 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 41 drugs

Part D claims

3,085

Median for Dermatology: 534

Drug cost

$683,713

Median for Dermatology: $67,151

Branded share of claims

17.8%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 89 $358,988
Cosentyx Unoready Pen Secukinumab Brand 13 $141,984
Humira(Cf) Pen Adalimumab Brand 11 $69,321
Pimecrolimus Generic 71 $19,975
Ketoconazole Generic 452 $11,488
Metronidazole Generic 154 $10,671
Ivermectin Generic 34 $7,883
Triamcinolone Acetonide Generic 529 $6,756
Azelaic Acid Generic 46 $5,811
Fluocinonide Generic 153 $4,958

The 10 drugs with the highest cost, of 41 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$72,611

Medicare's payments for the services billed

Medicare patients

686

Average age 76

Services billed

2,502

320 women, 366 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Chronic kidney disease 29%
Ischemic heart disease 26%
Diabetes 24%
Cancer 21%
Atrial fibrillation 15%
Depression 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
$761 — —
SKYRIZI
$401 — —
DUPIXENT
$304 89 —
Bimzelx
$281 — —
SOTYKTU
$267 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

1,165 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record